Breaking News Instant updates and real-time market news.

MMM

3M

$175.52

1.33 (0.76%)

, DWDP

DowDuPont

$30.99

0.75 (2.48%)

13:11
05/14/19
05/14
13:11
05/14/19
13:11

Attorney General, DEP sue 3M, DuPont over toxic chemicals, Insider NJ says

Attorney General Gurbir Grewal, Department of Environmental Protection Commissioner Catherine McCabe, and Acting Division of Consumer Affairs Director Paul Rodriguez announced that the State has filed a lawsuit against companies for manufacturing and selling firefighting foam products in New Jersey for decades despite knowing those products released toxic and harmful chemicals into the environment, according to Insider NJ. The State's complaint names several manufacturers and sellers as defendants, including 3M (MMM), DuPont (DWDP), and Chemours (CC), the report notes. Reference Link

MMM

3M

$175.52

1.33 (0.76%)

DWDP

DowDuPont

$30.99

0.75 (2.48%)

CC

Chemours

$25.32

-0.02 (-0.08%)

  • 14

    May

  • 14

    May

  • 15

    May

  • 18

    May

  • 23

    May

  • 29

    May

  • 05

    Jun

MMM 3M
$175.52

1.33 (0.76%)

04/29/19
04/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lionsgate (LGF, LGF.A, LGF.B) downgraded to In-Line from Outperform at Imperial Capital with analyst David Miller citing additional promotional expenses related to the Starz international rollout. 2. Occidental Petroleum (OXY) downgraded to Hold from Buy at Jefferies with analyst Jason Gammel saying the company's hostile counter-offer for Anadarko (APC) is a "risky but perhaps necessary move against a better-capitalized bidder for a company that rejected its initial overtures." 3. CVS Health (CVS) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying the stock faces a transitional year as it tries to drive seismic changes in healthcare. 4. Intel (INTC) downgraded to Hold from Buy at Argus with analyst Jim Kelleher citing the company's Q1 earnings miss and reduced FY19 outlook that reflected the company's Data Center Group weakness, which he calls "the linchpin of growth." 5. 3M (MMM) downgraded to Hold from Buy at Gordon Haskett with analyst John Inch downgraded saying his concerns extend beyond the company's Q1 earnings miss and steep guidance reduction. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/19
04/26/19
DOWNGRADE

Hold
3M downgraded to Hold from Buy at Argus
As previously reported, Argus analyst John Eade downgraded 3M to Hold after its Q1 earnings miss, saying the company has continued to "stumble" while "no longer delivering the consistent results that led to customary high valuations." The analyst notes that earnings could have been even worse, since the quarter did not include the $783M litigation-related charge. Eade expects 3M earnings and cash flows to be "challenging for several quarters" after Q1 commentary also revealed weakness in the company's end markets and "lackluster execution," but added that he would consider an upgrade if valuations on the stock compress toward the lower end of the company's historical range.
04/29/19
GDHS
04/29/19
DOWNGRADE
GDHS
Hold
3M downgraded to Hold from Buy at Gordon Haskett
04/29/19
GDHS
04/29/19
DOWNGRADE
Target $185
GDHS
Hold
Gordon Haskett downgrades 3M to Hold on execution concerns
As previously reported, Gordon Haskett analyst John Inch downgraded 3M to Hold from Buy, stating that his concerns extend beyond the company's Q1 earnings miss and steep guidance reduction. Self-help benefits that have been years in the making "have largely evaporated," while the "outsized decremental operating profit realized in the first quarter begs the question whether years of 3M footprint rationalization have actually made things worse," Inch tells investors in his downgrade note. 3M's response of cutting about 2% of the company's workforce doesn't seem "all that aggressive," added Inch, who wonders if it in fact may be an insufficient response. He lowered his price target on 3M shares to $185 from $222.
DWDP DowDuPont
$30.99

0.75 (2.48%)

05/03/19
FBCO
05/03/19
NO CHANGE
Target $43
FBCO
Outperform
DowDuPont post-spin investor fears 'overdone,' says Credit Suisse
Credit Suisse analyst Christopher Parkinson maintained an Outperform rating and $43 price target on DowDuPont following Thursday's earnings report, saying that while Q2 guidance was a "tough" lighter than expectations, he thinks post-spin investor fears are "overdone." Parkinson notes that there is an ongoing debate on Corteva's pro-forma valuation, which he understands given Q4 and Q1 volatility, but ultimately believes product quality and better confidence in the ag macro will assuage fears of a de-valuation.
05/07/19
RHCO
05/07/19
NO CHANGE
Target $37
RHCO
Hold
DowDuPont price target lowered to $37 from $41 at SunTrust
SunTrust analyst James Sheehan lowered his price target on DowDuPont to $37 and kept his Hold rating after its below-consensus Q1 revenue reported last week that was driven by adverse U.S. weather in the quarter impacting volumes. The analyst expects the challenging market conditions to persist in Q2 but also believes that the back half of the year will see some recovery in the Agriculture, Electronics, and Auto end markets. Sheehan sees DowDuPont shares trading in a range even after the June spin of Corteva given the U.S.-China trade uncertainty and auto/electronics headwinds.
04/16/19
04/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HollyFrontier (HFC) downgraded to Sell from Neutral at Goldman Sachs with analyst Neil Mehta saying he now sees a less attractive crude differential environment given a narrower Brent-WTI and WTI-WCS spread forecast in 2019 and 2020. 2. BP (BP) downgraded to Outperform from Top Pick at RBC Capital with analyst Biraj Borkhataria citing valuation. 3. Cisco (CSCO) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Rod Hall saying Cisco has executed well on rolling out its Catalyst 9000 products that have driven "solid" double digit growth in campus switching revenues. 4. DowDuPont (DWDP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the impact of the company's spinoff of Dow on April 2nd. 5. EOG Resources (EOG) and EQT Corporation (EQT) downgraded to Neutral from Buy at MKM Partners. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/19
04/16/19
DOWNGRADE
Target $40

Sector Perform
DowDuPont downgraded to Sector Perform at RBC Capital on Dow spinoff impact
As previously reported, RBC Capital analyst Arun Viswanathan downgraded DowDuPont to Sector Perform from Outperform and lowered his price target to $40 from $61, citing the impact of the company's spinoff of Dow on April 2nd. The analyst believes that DowDuPont's focus on its Specialty division opens it to the economic macro concerns in Europe and China. Viswanathan also points to the continued weakness in the company's Agriculture segment following the March floods in the Midwest as well as the separation costs related to the Dow spin and Corteva spin in June 2019, stating that DowDuPont looks "fairly priced at the current levels" given its two remaining divisions.
CC Chemours
$25.32

-0.02 (-0.08%)

05/06/19
JPMS
05/06/19
DOWNGRADE
Target $34
JPMS
Neutral
Chemours downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Chemours to Neutral from Overweight and lowered his price target for the shares to $34 from $40.
05/06/19
JPMS
05/06/19
DOWNGRADE
Target $34
JPMS
Neutral
JPMorgan downgrades Chemours to Neutral, prefers shares of Tronox
JPMorgan analyst Jeffrey Zekauskas downgraded Chemours (CC) to Neutral from Overweight and lowered his price target for the shares to $34 from $40. The company's Q1 volumes decreased 35% year-over-year, which might be expected in a recession "but it is not any kind of normal result in a growing economy," Zekauskas tells investors in a research note. The analyst decreased his EBITDA expectations, which brought his price target to $34, near the current Chemours share price. He prefers shares of Tronox (TROX) to Chemours.
05/06/19
RBCM
05/06/19
NO CHANGE
Target $43
RBCM
Outperform
Chemours price target lowered to $43 from $50 at RBC Capital
RBC Capital analyst Arun Viswanathan lowered his price target on Chemours to $43 after its Q1 earnings miss and "slightly bearish" management outlook for Q2. The analyst also warns that the performance in the Fluoroproducts segment could be similar in Q2 as in Q1 despite the management's forecast of improvement given the softer base refrigerant demand in North America. Viswanathan keeps his Outperform rating however and believes that titanium dioxide volumes could improve in the back half of 2019 as destocking activity runs its course.
04/15/19
04/15/19
UPGRADE
Target $52

Buy
Chemours upgraded to Buy at SunTrust on TiO2 price recovery
As previously reported, SunTrust analyst James Sheehan upgraded Chemours to Buy from Hold and raised his price target to $52 from $40. The analyst notes that "investor anxiety" about the titanium dioxide cycle has "largely dissipated" after inventory destocking ran its course and pricing declines moderated. The analyst also expects investors to consider Chemours' portfolio that includes a "compelling but overlooked long term growth story in Fluoroproducts" in addition to gaining "further evidence of pricing and margin stability" for TiO2 in 2019.

TODAY'S FREE FLY STORIES

SCON

Superconductor Technologies

$1.25

-0.065 (-4.94%)

16:52
05/20/19
05/20
16:52
05/20/19
16:52
Syndicate
Superconductor Technologies files to sell common stock, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

CCC

Clarivate Analytics

$13.34

-0.04 (-0.30%)

, INFO

IHS Markit

$57.51

0.12 (0.21%)

16:50
05/20/19
05/20
16:50
05/20/19
16:50
Hot Stocks
Clarivate Analytics names Jerre Stead as CEO, effective June 30 »

Clarivate Analytics (CCC)…

CCC

Clarivate Analytics

$13.34

-0.04 (-0.30%)

INFO

IHS Markit

$57.51

0.12 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:50
05/20/19
05/20
16:50
05/20/19
16:50
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson down 2.7% at $127…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

EBAY

eBay

$36.56

-0.34 (-0.92%)

16:47
05/20/19
05/20
16:47
05/20/19
16:47
Earnings
eBay VP Kristin Yetto sells over $940K shares of company stock »

eBay VP Kristin Yetto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

16:45
05/20/19
05/20
16:45
05/20/19
16:45
General news
Fed's Williams said the Fed has changed its view on the Phillips Curve relationship »

Fed's Williams said…

VNE

Veoneer

$18.89

0.02 (0.11%)

16:43
05/20/19
05/20
16:43
05/20/19
16:43
Syndicate
Veoneer files to sell $350M of common stock, $150M of convertible senior notes »

Veoneer announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    Jun

VYGR

Voyager Therapeutics

$21.87

-0.28 (-1.26%)

16:36
05/20/19
05/20
16:36
05/20/19
16:36
Hot Stocks
Voyager Therapeutics announces retirement of chief scientific officer Dinah Sah »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

16:35
05/20/19
05/20
16:35
05/20/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Ocular Therapeutix »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

HI

Hillenbrand

$38.98

0.05 (0.13%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Initiation
Hillenbrand initiated  »

Hillenbrand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Earnings
Varian Medical cuts FY19 adj. EPS view to $4.55-$4.70 from $4.60-$4.75 »

Consensus $4.70. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

MRK

Merck

$78.86

0.15 (0.19%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Hot Stocks
Merck announces Phase 3 KEYNOTE-119 trial does not meet OS primary endpoint »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Varian to acquire Cancer Treatment Services for $283M »

Varian Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Nordson CEO says 'continue to forecast organic growth' for 2019 »

CEO Michael Hilton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:32
05/20/19
05/20
16:32
05/20/19
16:32
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

REGN

Regeneron

$302.51

-2.3 (-0.75%)

, NVS

Novartis

$82.02

-0.7 (-0.85%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Regeneron, Novartis, Sanofi initiated at Credit Suisse »

Regeneron initiated with…

REGN

Regeneron

$302.51

-2.3 (-0.75%)

NVS

Novartis

$82.02

-0.7 (-0.85%)

SNY

Sanofi

$41.40

-0.53 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 23

    May

  • 31

    May

  • 14

    Jun

  • 26

    Jun

TMO

Thermo Fisher

$263.13

1.44 (0.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Thermo Fisher to invest $50M to expand bioproduction capabilities »

Thermo Fisher announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 31

    May

  • 02

    Dec

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Earnings
Nordson reports Q2 adjusted EPS $1.54, consensus $1.60 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NBIX

Neurocrine

$76.64

-2.39 (-3.02%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Neurocrine initiated  »

Neurocrine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

, TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Cohen & Steers names Paul Zettl chief marketing officer »

Paul Zettl has joined…

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

16:30
05/20/19
05/20
16:30
05/20/19
16:30
Options
Preliminary option volume of 17.5M today »

Preliminary option volume…

VRTX

Vertex

$165.71

-2.97 (-1.76%)

16:29
05/20/19
05/20
16:29
05/20/19
16:29
Initiation
Vertex initiated at Credit Suisse »

Vertex initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

16:28
05/20/19
05/20
16:28
05/20/19
16:28
Hot Stocks
Ascena Retail announces wind down of Dressbarn »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$65.85

-0.49 (-0.74%)

16:26
05/20/19
05/20
16:26
05/20/19
16:26
Initiation
Gilead initiated at Credit Suisse »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BIIB

Biogen

$230.70

1.49 (0.65%)

16:24
05/20/19
05/20
16:24
05/20/19
16:24
Initiation
Biogen initiated at Credit Suisse »

Biogen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWI

SolarWinds

$19.16

0.04 (0.21%)

16:23
05/20/19
05/20
16:23
05/20/19
16:23
Syndicate
SolarWinds files to sell 17.25M shares of common stock »

JPMorgan, Goldman Sachs,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.